CN1199651C - Astragalus root valid part of Chinese herbal medicine for treating cardiovascular disease - Google Patents
Astragalus root valid part of Chinese herbal medicine for treating cardiovascular disease Download PDFInfo
- Publication number
- CN1199651C CN1199651C CNB031133304A CN03113330A CN1199651C CN 1199651 C CN1199651 C CN 1199651C CN B031133304 A CNB031133304 A CN B031133304A CN 03113330 A CN03113330 A CN 03113330A CN 1199651 C CN1199651 C CN 1199651C
- Authority
- CN
- China
- Prior art keywords
- extract
- total saponins
- ethanol
- radix astragali
- dryness
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
一种具有保护心肌损伤作用的黄芪总皂甙,将黄芪乙醇提取物用水溶解,上大孔树脂柱,分别以水及含水乙醇洗脱,合并70%-98%乙醇洗脱液,蒸干得浸膏;用甲醇溶解浸膏,加硅藻土拌匀,硅藻土与浸膏比例为3-1∶1,以无水乙醇热回流提取,所得提取液蒸干,得皂甙提取物,其含总皂甙达85%-90%,总皂甙转移率在80%-85%。A kind of astragalus total saponins which has the effect of protecting myocardial injury, the ethanol extract of astragalus is dissolved in water, put on a macroporous resin column, eluted with water and ethanol containing water respectively, combined with 70%-98% ethanol eluate, evaporated to dryness to obtain Cream; dissolve the extract with methanol, add diatomaceous earth and mix well, the ratio of diatomaceous earth to extract is 3-1:1, extract with absolute ethanol under hot reflux, and evaporate the obtained extract to dryness to obtain saponin extract, which contains The total saponins reach 85%-90%, and the transfer rate of total saponins is 80%-85%.
Description
技术领域technical field
本发明通过制备方法的改进,获得具有保护心肌损伤作用的高纯度的黄芪总皂甙。The invention obtains high-purity total astragalus saponins with the effect of protecting myocardial damage through the improvement of the preparation method.
背景技术Background technique
黄芪(Radix astragali)为豆科植物蒙古黄芪Astragalus membranaceus(Fisch.)Bge.var mongholicus(Bge.)Hsiao或膜荚黄芪Astragalus membranaceus(Fisch.)Bge.的干燥根,性甘、温,归肺、脾经,补气固表,利尿托毒,排脓,敛疮生肌。现代化学研究证明黄芪药材中含有皂甙、多糖、黄酮、氨基酸、酚性化合物及微量元素等成分。黄芪皂甙具强心功能可用于治疗心衰,对急性心梗后心功能的恢复及氧自由基的清除具明显作用。尤其是近年来黄芪用于治疗病毒性心肌炎的研究,发现黄芪可抑制柯萨奇病毒的复制,对病毒感染心肌细胞异常电活动有逆转作用,经过比较研究了黄芪不同成分对病毒感染心肌细胞损伤的保护作用,证实了黄芪主要有效成分为黄芪总皂甙。但是黄芪皂甙含量较低,且根部含大量糖类物质,提取分离比较困难。Radix astragalus (Radix astragalus) is the dried root of Astragalus membranaceus (Fisch.) Bge.var mongholicus (Bge.) Hsiao or Astragalus membranaceus (Fisch.) Bge. of the leguminous plant Astragalus membranaceus (Fisch.) Bge. Spleen meridian, invigorating qi and solidifying the exterior, inducing diuresis to relieve toxins, evacuating pus, astringing sores and promoting granulation. Modern chemical research has proved that Astragalus contains saponins, polysaccharides, flavonoids, amino acids, phenolic compounds and trace elements. Astragaloside has a strong heart function and can be used to treat heart failure, and has a significant effect on the recovery of heart function after acute myocardial infarction and the scavenging of oxygen free radicals. Especially in recent years, astragalus has been used to treat viral myocarditis, and it has been found that astragalus can inhibit the replication of coxsackie virus and reverse the abnormal electrical activity of virus-infected myocardial cells. The protective effect of Astragalus proved that the main active ingredient of Astragalus is total saponins of Astragalus. However, the content of astragaloside is low, and the root contains a lot of sugar substances, so it is difficult to extract and separate.
现有提取分离工艺有:水提法、醇提法、树脂吸附法、正丁醇萃取法与超临界CO2法。为除去药材中的蔗糖、单糖,有用冷浸法(参见:无糖富集有效成分提取物及其制品,CN1171950A);水提醇沉法(参见:一种精制黄芪注射液制备工艺,CN1273116A)。Existing extraction and separation processes include: water extraction, alcohol extraction, resin adsorption, n-butanol extraction and supercritical CO 2 method. In order to remove sucrose and monosaccharides in medicinal materials, cold soaking method is useful (see: sugar-free enrichment active ingredient extract and its products, CN1171950A); ).
发明内容Contents of the invention
本发明要解决的技术问题是通过改进现有的黄芪有效部位黄芪皂甙的提取分离方法,以获得含量高、纯度提高的总皂甙,以确保疗效的稳定,并可具有更明确的质量控制指标。The technical problem to be solved by the present invention is to obtain total saponins with high content and improved purity by improving the existing method for extracting and separating astragalosides from effective parts of astragalus, so as to ensure stable curative effect and have clearer quality control indicators.
为解决上述问题,本发明提供如下技术解决方案:In order to solve the above problems, the present invention provides the following technical solutions:
一种黄芪皂甙,其特征在于可用下述方法得到:A kind of astragaloside is characterized in that available following method obtains:
1)取黄芪的乙醇提取物浸膏,用水溶解,上大孔树脂柱,用水与含水乙醇梯度洗脱,合并70%-98%乙醇洗脱液,得黄芪总皂甙粗品;1) Take the ethanol extract of Astragalus membranaceus, dissolve it in water, put it on a macroporous resin column, elute with water and ethanol containing water gradient, and combine the 70%-98% ethanol eluent to obtain the crude product of total saponins of Astragalus;
2)或者,取黄芪的乙醇提取物浸膏,用水溶解,先用0.1N的NaOH饱和的正丁醇萃取,浓缩萃取液至浸膏状,再用水溶解,上大孔树脂柱,用水与含水乙醇梯度洗脱,合并70%并70%-98%乙醇洗脱液,得黄芪总皂甙粗品;2) Alternatively, take the ethanol extract of Radix Astragali, dissolve it in water, first extract it with 0.1N NaOH-saturated n-butanol, concentrate the extract to an extract, then dissolve it in water, put it on a macroporous resin column, and mix it with water Ethanol gradient elution, combining 70% and 70%-98% ethanol eluents to obtain the crude product of astragalus total saponins;
3)或者,取黄芪的乙醇提取物浸膏,用甲醇溶解,加硅藻土拌匀,以无水乙醇热回流提取,所得提取液蒸干,得黄芪总皂甙粗品。3) Alternatively, take the ethanol extract of Astragalus membranaceus, dissolve it in methanol, add diatomaceous earth, mix well, extract with absolute ethanol under reflux, and evaporate the obtained extract to dryness to obtain crude total saponins of Astragalus membranaceus.
所述黄芪皂甙,其特征在于:The astragaloside is characterized in that:
将1)中的得到黄芪总皂甙粗品,用水溶解,再次上大孔树脂柱,用水与含水乙醇梯度洗脱,合并70%-98%乙醇洗脱液,得黄芪总皂甙;The crude product of total astragalosides obtained in 1) was dissolved in water, applied to a macroporous resin column again, gradient eluted with water and aqueous ethanol, and combined with 70%-98% ethanol eluents to obtain total astragalosides;
或者,将1)中的得到黄芪总皂甙粗品,用甲醇溶解,加硅藻土拌匀,以无水乙醇热回流提取,所得提取液蒸干,得黄芪总皂甙;Alternatively, the crude product of total astragalosides obtained in 1) is dissolved in methanol, mixed with diatomaceous earth, extracted with absolute ethanol under reflux, and the obtained extract is evaporated to dryness to obtain total astragalosides;
或者,将2)中的得到黄芪总皂甙粗品,用甲醇溶解,加硅藻土拌匀,以无水乙醇热回流提取,所得提取液蒸干,得黄芪总皂甙;Alternatively, the crude product of total astragalosides obtained in 2) is dissolved in methanol, mixed with diatomaceous earth, extracted with absolute ethanol under reflux, and the obtained extract is evaporated to dryness to obtain total astragalosides;
或者,将3)中的得到黄芪总皂甙粗品,用水溶解,上大孔树脂柱,用水与含水乙醇梯度洗脱,合并70%-98%乙醇洗脱液,得黄芪总皂甙;Alternatively, the crude product of total astragalosides obtained in 3) is dissolved in water, put on a macroporous resin column, gradient eluted with water and aqueous ethanol, and combined with 70%-98% ethanol eluents to obtain total astragalosides;
或者,将3)中的得到黄芪总皂甙粗品,用水溶解,先用碱水液饱和的正丁醇萃取,如用0.1N的NaOH饱和的正丁醇萃取,浓缩萃取液至浸膏状,再用水溶解,上大孔树脂柱,用水与含水乙醇梯度洗脱,合并70%-98%乙醇洗脱液,得黄芪总皂甙。Alternatively, the crude product of astragalus total saponins obtained in 3) is dissolved in water, first extracted with n-butanol saturated with alkaline aqueous solution, such as extracted with 0.1N NaOH saturated n-butanol, concentrated extract to an extract, and then Dissolve in water, apply to a macroporous resin column, elute with water and ethanol gradient, combine 70%-98% ethanol eluent to obtain total saponins of astragalus.
本发明所用大孔树脂柱的型号为D101、AB-8;乙醇提取物浸膏与硅藻土的重量比为1∶1-3;较好的乙醇提取物浸膏与硅藻土的重量比为为1∶2。The model of macroporous resin column used in the present invention is D101, AB-8; The weight ratio of ethanol extract extract and diatomaceous earth is 1: 1-3; The weight ratio of better ethanol extract extract and diatomite For 1:2.
用于防治心血管疾病的药物组合物,其中含有治疗有效量的权利要求1或2中任一项的黄芪皂甙和药学上可接受的载体。A pharmaceutical composition for preventing and treating cardiovascular diseases, which contains a therapeutically effective amount of astragaloside according to any one of claims 1 or 2 and a pharmaceutically acceptable carrier.
本发明通过所选择的大孔树脂柱层析及一定的洗脱条件,除去黄芪中大量的糖类物质,显著提高了总皂甙的含量。如果两次上大孔树脂柱,可极其显著提高所得浸膏的总皂甙含量。对于中药的色素等常见的影响制剂质量的杂质,一般常用活性碳去除,但本发明实验数据表明用活性碳除去色素等杂质往往大大降低了黄芪皂甙的收率,而本发明采取硅藻土拌匀,以无水乙醇热回流吸附法,去除色素等杂质的效果非常明显,且黄芪皂甙的收率亦高。本发明工艺中总皂甙的提取方式、提取溶剂、加溶剂量、回流时间、提取次数是经过正交设计研究而成,保证了所得到的黄芪总皂甙含量高,转移率大于80%。本发明与现有技术相比,具有总皂甙含量高、成本低、无有机溶剂残留以及生产过程对环境无污染等优点。The invention removes a large amount of carbohydrates in the astragalus through the selected macroporous resin column chromatography and certain elution conditions, and significantly increases the content of total saponins. If the macroporous resin column is applied twice, the total saponin content of the obtained extract can be significantly increased. Common impurities such as pigments in traditional Chinese medicines that affect the quality of preparations are generally removed by activated carbon, but the experimental data of the present invention shows that removing impurities such as pigments with activated carbon often greatly reduces the yield of astragaloside, and the present invention uses diatomite to mix Uniform, with absolute ethanol heat reflux adsorption method, the effect of removing impurities such as pigment is very obvious, and the yield of astragaloside is also high. The method of extracting total saponins in the process of the invention, the extraction solvent, the amount of solvent added, the reflux time and the number of times of extraction are obtained through orthogonal design and research, which ensures that the obtained astragalus total saponins has a high content and a transfer rate greater than 80%. Compared with the prior art, the invention has the advantages of high total saponin content, low cost, no organic solvent residue, no pollution to the environment in the production process and the like.
本发明的黄芪皂甙具有明显的保护心肌损伤作用。对于药品而言,其治疗组份的纯度与疗效密切相关。本发明通过改进现有的黄芪有效部位黄芪皂甙的提取分离方法,得到总皂甙含量大于80%的黄芪皂甙,纯度的提高,确保了在防治心血管疾病方面的稳定疗效,黄芪皂甙及含黄芪皂甙的药物组合物的质量稳定,质量控制指标明确。The astragaloside of the present invention has obvious effect of protecting myocardial injury. For pharmaceuticals, the purity of its therapeutic components is closely related to its efficacy. The present invention obtains astragaloside with a total saponin content greater than 80% by improving the existing method for extracting and separating astragaloside from the effective part of astragalus. The quality of the pharmaceutical composition is stable, and the quality control indicators are clear.
研究黄芪总皂甙(含量大于80%)的最佳工艺,该制备物具有保护心肌损伤的作用。To study the optimal technology of astragalus total saponins (content greater than 80%), the preparation has the effect of protecting myocardial injury.
其研究步骤和详细数据如下:The research steps and detailed data are as follows:
1.药材1. Medicinal materials
选用蒙古黄芪Astragalus membranaceus(Fisch.)Bge.varmongholicus(Bge.)Hsiao或膜荚黄芪Astragalus membranaceus(Fisch.)Bge.的干燥根。The dry root of Astragalus membranaceus (Fisch.) Bge.varmongholicus (Bge.) Hsiao or Astragalus membranaceus (Fisch.) Bge. is selected for use.
2.总皂甙提取方式的影响:2. The influence of the extraction method of total saponins:
取粉碎成40目的黄芪药材粉末50g,精密称定,分别按下列方法提取:Take 50 g of astragalus medicinal material powder crushed into 40 meshes, accurately weighed, and extract according to the following methods respectively:
(1)水提醇沉:取药材50g,加蒸馏水200ml,加热提取3次,每次1.5h,水液离心,上清液合并,浓缩至适量,加95%乙醇沉淀,静置12h,离心,取上清液合并,浓缩得浸膏。(1) Water extraction and alcohol precipitation: Take 50g of medicinal materials, add 200ml of distilled water, heat and extract 3 times, each time for 1.5h, centrifuge the water and liquid, combine the supernatant, concentrate to an appropriate amount, add 95% ethanol for precipitation, stand for 12h, and centrifuge , and the supernatants were combined and concentrated to obtain the extract.
(2)50%醇提液:取药材50g,加50%乙醇200ml,90℃加热回流3次,每次1.5h,合并提取液,浓缩得浸膏。(2) 50% alcohol extract: Take 50g of medicinal materials, add 200ml of 50% ethanol, heat and reflux at 90°C for 3 times, each time for 1.5h, combine the extracts, and concentrate to obtain the extract.
(3)70%醇提液:取药材50g,加70%乙醇200ml,90℃加热回流3次,每次1.5h,合并提取液,浓缩得浸膏。(3) 70% alcohol extract: Take 50g of medicinal materials, add 200ml of 70% ethanol, heat and reflux at 90°C for 3 times, each time for 1.5h, combine the extracts, and concentrate to obtain the extract.
(4)95%乙醇提取液:取药材50g,加95%乙醇200ml,90℃加热回流3次,每次1.5h,合并提取液,浓缩得浸膏。(4) 95% ethanol extract: Take 50 g of medicinal materials, add 200 ml of 95% ethanol, heat and reflux at 90° C. for 3 times, each time for 1.5 h, combine the extracts, and concentrate to obtain an extract.
实验证明:浸膏得率为50%醇提液>70%醇提液>95%醇提液>水提醇沉。The experiment proves that the extract yield rate is 50% alcohol extract > 70% alcohol extract > 95% alcohol extract > water extraction and alcohol precipitation.
3、黄芪总皂甙的分离、纯化、浓缩与干燥工艺3. Separation, purification, concentration and drying process of total astragalus saponins
3.1分离与纯化工艺3.1 Separation and purification process
取蒙古黄芪或膜荚黄芪药材,先将药材粉碎,以50-95%乙醇加热回流提取3次,每次加50-95%乙醇10倍量,提取1.5h/次。合并提取液,得浸膏A。Take Astragalus mongolica or Astragalus membranaceus, crush the medicinal materials, heat and reflux extraction with 50-95% ethanol for 3 times, add 10 times the amount of 50-95% ethanol each time, and extract for 1.5h/time. The extracts were combined to obtain extract A.
将浸膏A以适量蒸馏水溶解,上大孔树脂柱,分别以蒸馏水、20%、30%、40%、50%、60%、70%、80%、90%、98%乙醇洗脱,合并70%-98%乙醇洗脱液,蒸干得浸膏B。Dissolve the extract A with an appropriate amount of distilled water, put it on a macroporous resin column, elute with distilled water, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, and 98% ethanol, and combine 70%-98% ethanol eluate was evaporated to dryness to obtain extract B.
将浸膏B以甲醇溶解,加硅藻土拌匀,硅藻土与浸膏比例为3-1∶1,以2∶1为好,用无水乙醇热回流提取3次,所得提取液蒸干,得提取物I,以黄芪甲苷计算,该提取物含总皂甙达85%-90%,总皂甙转移率在80%-85%。Dissolve extract B in methanol, add diatomaceous earth and mix well, the ratio of diatomaceous earth to extract is 3-1:1, preferably 2:1, extract with absolute ethanol under reflux for 3 times, and the obtained extract is distilled Dry to obtain extract I. Calculated by astragaloside IV, the extract contains 85%-90% of total saponins, and the transfer rate of total saponins is 80%-85%.
若将此提取物I以蒸馏水溶解,上大孔树脂柱,分别以蒸馏水、20%、30%、40%、50%、60%、70%、80%乙醇洗脱,合并50%-80%乙醇流份,蒸干,得提取物II,以黄芪甲苷计算,该提取物含总皂甙达98%以上,总皂甙转移率在75%-80%。If the extract I is dissolved in distilled water, put on a macroporous resin column, elute with distilled water, 20%, 30%, 40%, 50%, 60%, 70%, and 80% ethanol respectively, and combine 50%-80% Ethanol fractions were evaporated to dryness to obtain extract II. Calculated by astragaloside IV, the extract contained more than 98% of total saponins, and the transfer rate of total saponins was 75%-80%.
3.2浓缩与干燥工艺3.2 Concentration and drying process
将70%-98%乙醇洗脱液减压回收溶剂,真空干燥,即得总皂甙部位。Recover the solvent from the 70%-98% ethanol eluent under reduced pressure, and dry it in vacuum to obtain the total saponins.
本发明的黄芪总皂甙对培养心肌细胞的保护作用Protective effect of total astragalus saponins of the present invention on cultured cardiomyocytes
1、黄芪总皂甙对培养心肌细胞钙超载的影响1. Effect of Astragalus total saponins on calcium overload of cultured cardiomyocytes
(1)黄芪总皂甙对心肌细胞游离钙的影响(1) Effect of Astragalus total saponins on free calcium in cardiomyocytes
黄芪总皂甙单独干预细胞对胞内游离钙离子([Ca2+]i)无影响,但是与异丙肾上腺素同时作用时,黄芪总皂甙可抑制异丙肾上腺素引起的[Ca2+]i的增加。与异丙肾上腺素比较,黄芪总皂甙从低浓度到高浓度(10,100,200mg·ml-1),分别降低[Ca2+]i39%,40%,51%(P<0.05)。Total astragalosides intervening cells alone had no effect on intracellular free calcium ions ([Ca 2+ ] i ), but when they acted together with isoproterenol, total astragalosides could inhibit [Ca 2+ ] i induced by isoproterenol increase. Compared with isoproterenol, astragalus total saponins decreased [Ca 2+ ] i by 39%, 40%, and 51% from low concentration to high concentration (10, 100, 200 mg·ml -1 ), respectively (P<0.05).
(2)黄芪总皂甙对心肌细胞肌浆网钙负荷的影响(2) Effects of total saponins of astragalus on the calcium loading of cardiomyocyte sarcoplasmic reticulum
黄芪总皂甙单独干预细胞对肌浆网钙负荷(Sarcoplasmic reticulum Calcium load)无影响,异丙肾上腺素可使肌浆网钙负荷增加145%(P<0.01),与异丙肾上腺素同时作用时,黄芪总皂甙可抑制异丙肾上腺素引起的肌浆网钙负荷的增加,从低浓度到高浓度分别降低11%(P>0.05),35%(P<0.05),51%(P<0.05)。Astragalus total saponins intervening cells alone has no effect on sarcoplasmic reticulum calcium load (Sarcoplasmic reticulum Calcium load), isoproterenol can increase sarcoplasmic reticulum calcium load by 145% (P<0.01), when it acts simultaneously with isoproterenol, Astragalus total saponins can inhibit the increase of sarcoplasmic reticulum calcium load caused by isoproterenol, from low concentration to high concentration respectively decreased by 11% (P>0.05), 35% (P<0.05), 51% (P<0.05) .
(3)黄芪总皂甙对心肌细胞肌浆网Ca2+-ATPase活性的影响(3) Effect of total saponins of astragalus on Ca 2+ -ATPase activity of cardiomyocyte sarcoplasmic reticulum
黄芪总皂甙单独干预细胞可使肌浆网Ca2+-ATPase活性增加,但与异丙肾上腺素同时作用时,黄芪总皂甙可抑制异丙肾上腺素引起的肌浆网Ca2+-ATPase活性的增加,在高浓度组可抑制34%(P<0.05)。Astragalus total saponins intervening cells alone can increase the activity of sarcoplasmic reticulum Ca 2+ -ATPase . increase, and it can be inhibited by 34% in the high concentration group (P<0.05).
2、黄芪总皂甙对培养心肌细胞损伤指标(肌钙蛋白I)的检测2. Detection of Astragalus total saponins on the injury index (Troponin I) of cultured cardiomyocytes
黄芪总皂甙作用于培养心肌细胞,检测上清中心肌细胞损伤指标——肌钙蛋白I(cTnI),发现与正常对照组比较cTnI无变化,表明黄芪总皂甙对心肌细胞无损伤。Astragalus total saponins acted on the cultured cardiomyocytes, and the myocardial cell injury index in the supernatant - troponin I (cTnI) was detected, and there was no change in cTnI compared with the normal control group, indicating that astragalus total saponins had no damage to cardiomyocytes.
具体实施方式Detailed ways
选用《中华人民共和国药典》(2000年版)收载的下列2种黄芪药材中其中的一种,即:蒙古黄芪Astragalus membranaceus(Fisch.)Bge.var mongholicus(Bge.)Hsiao或膜荚黄芪Astragalus membranaceus(Fisch.)Bge.的干燥根。药材的性状特征、理化鉴别特征符合《中华人民共和国药典》(2000年版一部)“黄芪”项下内容。Choose one of the following two kinds of Astragalus membranaceus (Fisch.) Bge. (Fisch.) Dried root of Bge. The traits and physical and chemical identification characteristics of the medicinal materials are in line with the content under the item "Astragalus" in the Pharmacopoeia of the People's Republic of China (1st Edition, 2000).
实施例1Example 1
称取黄芪药材20kg,粉碎,过20目筛,加8倍量的50%乙醇,80℃提取3次,每次.5小时。合并提取液,得浸膏A。将浸膏A以适量蒸馏水溶解,以0.1N NaOH饱和的正丁醇萃取3次,合并萃取液,得浸膏B,将浸膏B以蒸馏水溶解,上大孔树脂柱,分别以蒸馏水、、20%、30%、40%、50%、60%、70%、80%、90%、98%乙醇洗脱,合并70%-98%乙醇洗脱液,蒸干,得提取物I,以黄芪甲苷计算,该提取物含总皂甙达75.6%,总皂甙转移率在80.0%。Weigh 20kg of Radix Astragali, pulverize, pass through a 20-mesh sieve, add 8 times the amount of 50% ethanol, and extract at 80°C for 3 times, each time for .5 hours. The extracts were combined to obtain extract A. Dissolve the extract A with an appropriate amount of distilled water, extract three times with n-butanol saturated with 0.1N NaOH, combine the extracts to obtain extract B, dissolve the extract B with distilled water, put it on a macroporous resin column, and wash it with distilled water, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 98% ethanol elution, combined 70%-98% ethanol eluent, evaporated to dryness to obtain extract I, and According to the calculation of astragaloside IV, the extract contains 75.6% of total saponins, and the transfer rate of total saponins is 80.0%.
实施例2Example 2
称取黄芪药材20kg,粉碎,过20目筛,加10倍量的95%乙醇,90℃提取3次,每次1.5小时。合并提取液,得浸膏A。将浸膏A以适量蒸馏水溶解,以0.1N NaOH饱和的正丁醇萃取3次,合并萃取液,得浸膏B,将浸膏B以蒸馏水溶解,上大孔树脂柱,分别以蒸馏水、20%、30%、40%、50%、60%、70%、80%、90%、98%乙醇洗脱,合并70%-98%乙醇洗脱液,蒸干得浸膏C。将浸膏C以甲醇溶解,加硅藻土拌匀,硅藻土与浸膏比例为2∶1,以无水乙醇热回流提取3次,所得提取液蒸干,得提取物I,以黄芪甲苷计算,该提取物含总皂甙达85.2%,总皂甙转移率在72.5%。Weigh 20 kg of Radix Astragali, pulverize, pass through a 20-mesh sieve, add 10 times the amount of 95% ethanol, and extract at 90° C. for 3 times, each time for 1.5 hours. The extracts were combined to obtain extract A. Dissolve the extract A with an appropriate amount of distilled water, extract three times with 0.1N NaOH-saturated n-butanol, combine the extracts to obtain extract B, dissolve the extract B with distilled water, put it on a macroporous resin column, and wash it with distilled water, 20 %, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 98% ethanol elution, combined 70%-98% ethanol eluent, evaporated to dryness to obtain extract C. Dissolve the extract C in methanol, add diatomaceous earth and mix well, the ratio of diatomaceous earth to extract is 2:1, extract 3 times with absolute ethanol under reflux, and evaporate the obtained extract to dryness to obtain extract I. According to the calculation of glycosides, the extract contains 85.2% of total saponins, and the transfer rate of total saponins is 72.5%.
实施例3Example 3
称取黄芪药材20kg,粉碎,过20目筛,加10倍量的70%乙醇,80℃提取3次,每次1.5小时。合并提取液,得浸膏。将此浸膏以适量蒸馏水溶解,上大孔树脂柱,分别以蒸馏水、20%、30%、40%、50%、60%、70%、80%、90%、98%乙醇洗脱,合并70%-98%乙醇洗脱液,蒸干得浸膏B。将浸膏B以甲醇溶解,加硅藻土拌匀,硅藻土与浸膏比例为2∶1,以无水乙醇热回流提取3次,所得提取液蒸干,得提取物I,以黄芪甲苷计算,该提取物含总皂甙达83.4%,总皂甙转移率在81.2%。Weigh 20 kg of Radix Astragali, pulverize, pass through a 20-mesh sieve, add 10 times the amount of 70% ethanol, and extract at 80° C. for 3 times, each time for 1.5 hours. Combine the extracts to obtain the extract. Dissolve this extract with an appropriate amount of distilled water, put it on a macroporous resin column, elute with distilled water, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, and 98% ethanol respectively, and combine 70%-98% ethanol eluate was evaporated to dryness to obtain extract B. Dissolve extract B in methanol, add diatomaceous earth and mix well, the ratio of diatomaceous earth to extract is 2:1, extract 3 times with absolute ethanol under reflux, and evaporate the obtained extract to dryness to obtain extract I. According to the calculation of glycosides, the extract contains 83.4% of total saponins, and the transfer rate of total saponins is 81.2%.
实施例4Example 4
称取黄芪药材20kg,粉碎,过20目筛,加12倍量的50%乙醇,90℃提取3次,每次1.5小时。合并提取液,得浸膏,将此浸膏以适量蒸馏水溶解,上大孔树脂柱,分别以蒸馏水、20%、30%、40%、50%、60%、70%、80%、90%、98%乙醇洗脱,合并40%-98%乙醇洗脱液,蒸干得提取物I,以黄芪甲苷计算,该提取物含总皂甙达74.8%,总皂甙转移率在85.1%。Weigh 20kg of Radix Astragali, pulverize, pass through a 20-mesh sieve, add 12 times the amount of 50% ethanol, and extract at 90°C for 3 times, each time for 1.5 hours. Combine the extracts to obtain the extract, dissolve the extract with an appropriate amount of distilled water, put it on a macroporous resin column, and add distilled water, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% , 98% ethanol elution, combined 40%-98% ethanol eluent, evaporated to dryness to obtain extract I, calculated astragaloside IV, this extract contains total saponins up to 74.8%, and the total saponin transfer rate is 85.1%.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031133304A CN1199651C (en) | 2003-04-29 | 2003-04-29 | Astragalus root valid part of Chinese herbal medicine for treating cardiovascular disease |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031133304A CN1199651C (en) | 2003-04-29 | 2003-04-29 | Astragalus root valid part of Chinese herbal medicine for treating cardiovascular disease |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1444949A CN1444949A (en) | 2003-10-01 |
CN1199651C true CN1199651C (en) | 2005-05-04 |
Family
ID=27814704
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB031133304A Expired - Fee Related CN1199651C (en) | 2003-04-29 | 2003-04-29 | Astragalus root valid part of Chinese herbal medicine for treating cardiovascular disease |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1199651C (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100434093C (en) * | 2004-02-11 | 2008-11-19 | 吴芳 | 'Kidney-Benefiting' glucose injection and its preparing process |
CN100459987C (en) * | 2004-02-23 | 2009-02-11 | 江苏省药物研究所 | A kind of effective part of Radix Astragali and its preparation method and application in pharmacy |
CN1785202B (en) * | 2004-12-06 | 2010-12-01 | 天津天士力制药股份有限公司 | Medicinal composition for treating cardiovascular disease and its preparation method |
CN100441203C (en) * | 2005-02-24 | 2008-12-10 | 四川科伦药业股份有限公司 | Preparation method of astragaloside for injection |
CN102133262A (en) * | 2011-03-13 | 2011-07-27 | 浙江大学 | Preparation method and application of Astragalus membranaceus active constituent with effect of myocardium protection |
-
2003
- 2003-04-29 CN CNB031133304A patent/CN1199651C/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1444949A (en) | 2003-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100560083C (en) | A preparation method for extracting and purifying total saponins from Chinese medicine Panax notoginseng | |
CN102423329B (en) | A kind of discoloration method of panax notoginsenoside extract | |
CN103180334B (en) | Prepare the method for lactone glucoside of Radix Paeoniae and peoniflorin | |
CN1709885A (en) | Scutellaria baicalensis total flavonoid aglycon extract, scutellaria baicalensis monomeric flavonoid aglycone and preparation method and application thereof | |
CN101348474A (en) | Method for preparing salvianolic acid B and tanshinol from Salvia miltiorrhiza stem | |
WO2012019373A1 (en) | Method for preparing paeoniflorin and albiflorin | |
CN1876641B (en) | Method for purifying salvianolic acid B | |
CN102134268B (en) | Method for preparing panax japonicus saponin IVa and application of panax japonicus saponin IVa in preparing a medicament for protecting liver and lowering transaminase | |
CN107118219B (en) | The method of separating-purifying gelsevirine, koumidine, koumine, gelsemine and furans koumine from elegant jessamine | |
CN101991578A (en) | Application of asiatic acid and madecassic acid in preparation of alpha-glucosidase inhibitor drugs | |
CN1199651C (en) | Astragalus root valid part of Chinese herbal medicine for treating cardiovascular disease | |
CN101234147A (en) | Preparation method of total flavonoids from Trollus chinensis for injection | |
CN1221267C (en) | Feeze-dried powder injection contg. tatol saponin by refinement of American ginseng and leaves and stem of Americal ginseng, and its prodn. process | |
CN107929544A (en) | The preparation method and applications of militarine positions and monomer in bletilla platymiscium | |
CN103381200A (en) | White mulberry root-bark total alkaloid extract and preparation and application thereof | |
CN106822331A (en) | To lock application of the lichee bark extract based on shape polymer polyphenol in treatment antihyperuricemic disease drug or health products are prepared | |
CN101638404B (en) | High-purity salvianolic acid B and preparation method and application thereof | |
CN1733131A (en) | Schisandra fruit extractive, its preparation process and purposes | |
CN1833692A (en) | False portulaca oleracea extracts, its prepn. and usage | |
CN101139378A (en) | A method for extracting calycosin-7-O-β-D-glucoside from Radix Astragali | |
CN1157414C (en) | Extraction and separation method of astragalus polysaccharide and astragaloside | |
CN1446818A (en) | Technique of preparing extract product of Radde Anemone Rhizome extract, and its application in preparing medication of treating cancer | |
CN1887894A (en) | Extraction and application of anthraglucorhein and rhubarb aglycone | |
CN102659740A (en) | Method for extracting quercetin from eucommia leaves | |
CN1686258A (en) | Thesium Chinese total flavone preparation method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: CHINA PHARMACY UNIVERSITY; NO.1 ATTACHED HOSPITAL Free format text: FORMER OWNER: CHINA PHARMACY UNIVERSITY Effective date: 20060721 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20060721 Address after: Nanjing City, Jiangsu Province, Tong Lane 210009 No. 24 Co-patentee after: No.1 Attached Hospital, Nanjing Medical Univ. Patentee after: China Pharmaceutical University Co-patentee after: Nanjing Medical University Address before: Nanjing City, Jiangsu Province, Tong Lane 210009 No. 24 Patentee before: China Pharmaceutical University |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050504 Termination date: 20120429 |